BR0010794A - Emulsão-veìculo para drogas com fraca solubilidade - Google Patents

Emulsão-veìculo para drogas com fraca solubilidade

Info

Publication number
BR0010794A
BR0010794A BR0010794-8A BR0010794A BR0010794A BR 0010794 A BR0010794 A BR 0010794A BR 0010794 A BR0010794 A BR 0010794A BR 0010794 A BR0010794 A BR 0010794A
Authority
BR
Brazil
Prior art keywords
emulsion
vehicle
drugs
polyethylene glycol
vitamin
Prior art date
Application number
BR0010794-8A
Other languages
English (en)
Inventor
Karel J Lambert
Panayiotis P Constantinides
Steven C Quay
Alexander K Tustian
Original Assignee
Sonus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/317,499 external-priority patent/US6660286B1/en
Application filed by Sonus Pharma Inc filed Critical Sonus Pharma Inc
Publication of BR0010794A publication Critical patent/BR0010794A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"EMULSãO-VEìCULO PARA DROGAS COM FRACA SOLUBILIDADE". é revelada uma emulsão que incorpora um ou mais tocóis, um co-solvente e, estabilizada por tensoativos biocompatíveis, como um veículo ou portador para as drogas terapêuticas, a qual é substancialmente livre de etanol e que pode ser administrada a animais ou humanos através de diversas rotas de administração. Também incluída na emulsão está a vitamina C polietilenoglicolada. Os <244>-tocoferóis polietilenoglicolados incluem subunidades de polietileno glicol anexadas por um diéster do ácido succínico no anel hidroxila da vitamina E, e servem como um tensoativo primário, estabilizador e um solvente secundário em emulsões tocóis.
BR0010794-8A 1999-05-24 2000-05-17 Emulsão-veìculo para drogas com fraca solubilidade BR0010794A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31749599A 1999-05-24 1999-05-24
US09/317,499 US6660286B1 (en) 1997-01-07 1999-05-24 Emulsion vehicle for poorly soluble drugs
US15612899P 1999-09-27 1999-09-27
PCT/US2000/013572 WO2000071163A1 (en) 1999-05-24 2000-05-17 Emulsion vehicle for poorly soluble drugs

Publications (1)

Publication Number Publication Date
BR0010794A true BR0010794A (pt) 2002-06-04

Family

ID=27387807

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010794-8A BR0010794A (pt) 1999-05-24 2000-05-17 Emulsão-veìculo para drogas com fraca solubilidade

Country Status (9)

Country Link
EP (1) EP1185301A1 (pt)
JP (1) JP2003500368A (pt)
KR (1) KR20070058028A (pt)
AU (1) AU5273200A (pt)
BR (1) BR0010794A (pt)
CA (1) CA2373994A1 (pt)
MX (1) MXPA01011981A (pt)
TW (1) TWI290052B (pt)
WO (1) WO2000071163A1 (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
KR20020059415A (ko) 1999-09-27 2002-07-12 스티븐 씨. 큐웨이 토콜-가용성 치료요법제
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
WO2002026208A2 (en) * 2000-09-27 2002-04-04 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
AU2002239282A1 (en) 2000-11-28 2002-06-11 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
FR2820975B1 (fr) * 2001-02-21 2004-03-12 Oreal Composition pour application topique comprenant au moins un hydroxystilbene et au moins un polyol pour solubiliser l'hydroxystilbene
US6858227B1 (en) 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
AU2002347541A1 (en) * 2001-12-13 2003-06-23 Ranbaxy Laboratories Limited Stable topical formulation of clarithromycin
DK1463487T3 (da) * 2001-12-19 2010-08-23 Res Dev Foundation Liposomal afgivelse af vitamin-E baserede forbindelser
CA2472578A1 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
ES2330326T3 (es) 2002-05-24 2009-12-09 Angiotech International Ag Composiciones y metodos para recubrir implantes medicos.
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
KR100996996B1 (ko) 2002-11-07 2010-11-25 코산 바이오사이언시즈, 인코포레이티드 트랜스-9,10-디히드로에포틸론 c 및 d, 그것의 유사체 및 그것의 제조 방법
JPWO2004073692A1 (ja) * 2003-02-18 2006-06-01 山下 伸二 難水溶性薬物のハードカプセル剤
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
FR2855521B1 (fr) 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
CA2536283A1 (en) * 2003-08-20 2005-03-03 Ajinomoto Co., Inc. Pharmaceutical preparations having an improved solubility
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
DE602004027936D1 (de) * 2003-10-29 2010-08-12 Sonus Pharmaceutical Inc Tocopherolmodifizierte therapeutische arzneimittelverbindung
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
ATE516011T1 (de) * 2003-12-19 2011-07-15 Schering Corp Pharmazeutische zusammensetzungen eines a2a rezeptorantagonisten
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
MX344532B (es) 2004-10-01 2016-12-19 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
CA2597590A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
EP1853250B1 (en) 2005-02-18 2011-11-02 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
WO2006098241A1 (ja) * 2005-03-14 2006-09-21 Otsuka Pharmaceutical Factory, Inc. 難水溶性薬物を含有する医薬組成物
CA2604473A1 (en) 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
KR101271263B1 (ko) * 2005-09-28 2013-06-07 아우리스 메디칼 아게 내이 장애 치료용 약학 조성물
US8703195B2 (en) * 2006-03-10 2014-04-22 Biorem Ag Method for solubilising, dispersing and stabilising of substances, products manufactured according to the method as well as the use thereof
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
US8980323B2 (en) 2006-08-29 2015-03-17 Fujifilm Corporation Hydrophilic matrix containing poorly water-soluble compound and method for producing the same
WO2008088037A1 (ja) * 2007-01-18 2008-07-24 National University Corporation Chiba University 微粒子製剤
WO2009084801A1 (en) * 2007-12-31 2009-07-09 Samyang Corporation Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same
KR101024742B1 (ko) * 2007-12-31 2011-03-24 주식회사 삼양사 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법
US9801818B2 (en) 2007-12-31 2017-10-31 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
SG178403A1 (en) * 2009-08-14 2012-03-29 Opko Health Inc Intravenous formulations of neurokinin-1 antagonists
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011038073A1 (en) 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes comprising docetaxel
US9314509B2 (en) * 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
US20110144578A1 (en) * 2009-12-11 2011-06-16 Stephen Pacetti Hydrophobic therapueutic agent and solid emulsifier coating for drug coated balloon
CN102101863B (zh) 2009-12-17 2014-10-15 唐莉 新型环氧噻酮化合物及其制备方法和用途
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前-乳劑調配物及其製造與使用之方法
JP5876467B2 (ja) * 2010-03-17 2016-03-02 クローダ,インコーポレイティド ポリマー界面活性剤
WO2011123395A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
ES2925531T3 (es) 2010-03-29 2022-10-18 Abraxis Bioscience Llc Procedimientos para mejorar la administración de fármacos y la eficacia de agentes terapéuticos
CA2801645A1 (en) 2010-06-04 2011-12-08 Abraxis Bioscience, Llc Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer
CA2802767C (en) * 2010-08-04 2019-08-13 Gruenenthal Gmbh Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
PL2701684T3 (pl) 2011-04-28 2018-09-28 Platform Brightworks Two, Ltd. Ulepszone preparaty pozajelitowe lipofilowych środków farmaceutycznych oraz sposoby ich wytwarzania i stosowania
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
WO2018005412A1 (en) * 2016-06-28 2018-01-04 Tien Yang Der Chemoprotective/chemoactive nanodroplets and methods of use thereof
JP2018024592A (ja) * 2016-08-09 2018-02-15 株式会社ブレインヘルス 抗生物質含有組成物
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3424494A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
EP3424493A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
KR102197257B1 (ko) * 2017-10-19 2020-12-31 단국대학교 천안캠퍼스 산학협력단 엔테카비어 지방산 에스테르 유도체 수성현탁액의 안정화 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169846A (en) * 1989-10-12 1992-12-08 Crooks Michael J Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
KR100239799B1 (ko) * 1995-01-21 2000-02-01 손경식 경구투여용 사이클로스포린 에이 고체미셀분산체, 이의 제조 방법 및 고형제제
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
NZ314060A (en) * 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
KR20010006480A (ko) * 1997-04-18 2001-01-26 우에하라 아끼라 마이크로에멀젼
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations

Also Published As

Publication number Publication date
KR20070058028A (ko) 2007-06-07
AU5273200A (en) 2000-12-12
MXPA01011981A (es) 2003-09-04
CA2373994A1 (en) 2000-11-30
JP2003500368A (ja) 2003-01-07
TWI290052B (en) 2007-11-21
EP1185301A1 (en) 2002-03-13
WO2000071163A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
BR0010794A (pt) Emulsão-veìculo para drogas com fraca solubilidade
CA2276730A1 (en) Emulsion vehicle for poorly soluble drugs
ES2586032T3 (es) Administración de composiciones de benzodiazepinas
US20120202892A1 (en) Cannabinoid-Containing Compositions and Methods for Their Use
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
ES2262202T3 (es) Uso de acido 5-metil- (6s)-tetrahidrofolico para la prevencion de defectos del tubo neural.
BR0005287A (pt) Método para preparação de uma micropartìcula de liberação prolongada e micropartìcula de liberação prolongada assim obtida
EA200601724A1 (ru) Новые композиции для местной доставки
US20120202891A1 (en) Cannabinoid-Containing Compositions and Methods for Their Use
ES2162656T3 (es) Derivados de quinazolina.
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
BR0309138A (pt) Processo para a preparação de uma composição farmacêutica finamente auto-emulsionável
BR0108930A (pt) Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente
GT199900131A (es) Derivados del acido hidroxi-pipecolato hidroxamico.
BR9813947A (pt) Composições tópicas para distribuição de droga nsai
BR9909796B1 (pt) &#34;derivados de piperidinopirimidina para aplicação tópica&#34;
AU2018296678A1 (en) Stable cannabinoid compositions
BR0313060A (pt) Composições farmacêuticas aquosas de 2,6-diisopropilfenol
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
BRPI0411017A (pt) indóis 3-substituìdos e derivados dos mesmos como agentes terapêuticos
KR970704452A (ko) 앨러지성 안질환을 치료하기 위한 독세핀 유도체를 함유하는 국소적 안과용 제제(Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases)
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
KR960704543A (ko) 악성 질환의 치료를 위한 비경구투여용 부설판(Parenteral Busulfan for treatment of malignant disease)
MX9400037A (es) Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A,10AE 11A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.